Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES

Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES

The present study is designed to determine the mutational status of markers (TET2 and PLCb2, cytogenetic aberrations) together with methylation status of the above genes using bone marrow and matched buccal cell samples from MDS patients who necessitate to start a treatment (i.e. EPO, Lenalidomide, Azacytidine). All patients included in the study will be followed for at least 2 years.

Inclusion Criteria:

• Written informed consent
• Patients diagnosed with MDS according to FAB, WHO and IPSS classifications
• All clinically treatable MDS patients with EPO or Lenalidomide or 5-Azacytidine;
• Hb < 10 g/dL
• Age ≥ 18 years
• Gender: Male or Female
• Sufficient amount of biological samples for molecular studies

Exclusion Criteria:

• Age <18 years
• Patients who do not require treatment on "watch and wait" strategy
• Insufficient amount of biological samples for molecular studies